Suppr超能文献

减低剂量预处理:大剂量治疗后难治性淋巴恶性肿瘤经减低剂量预处理和异基因移植后的移植物抗肿瘤效应增强

Reduced intensity conditioning: enhanced graft-versus-tumor effect following dose-reduced conditioning and allogeneic transplantation for refractory lymphoid malignancies after high-dose therapy.

作者信息

Mohty M, Fegueux N, Exbrayat C, Lu Z Y, Legouffe E, Quittet P, Lopez-Martinez E, Latry P, Avinens O, Hertog C, Klein B, Eliaou J F, Rossi J F

机构信息

Hématologie et Oncologie Médicale, CHU de Montpellier, Montpellier, France.

出版信息

Bone Marrow Transplant. 2001 Aug;28(4):335-9. doi: 10.1038/sj.bmt.1703134.

Abstract

Non-myeloablative regimens have been proven to allow engraftment following allogeneic stem cells transplantation (allo-SCT) with minimal procedure-related toxicity. Conventional allo-SCT may produce remissions in patients with relapsed and refractory lymphoid malignancies (LM) but these good results may be achieved at the cost of high treatment-related morbidity and mortality. Application of allo-SCT using less intensive regimens may temper the frequency of these complications, allowing a potent graft-versus-tumor effect (GVT). We present our data on 11 patients with LM receiving allo-SCT with a reduced regimen. Ten patients had received previous high-dose therapy, and were at high risk for toxicity, thus precluding the use of allo-SCT. A fludarabine and low-dose busulfan combination facilitated engraftment while exerting GVT. Hematological recovery was quick, and full donor T cell chimerism preceded acute GVHD. GVHD and infections were the major problems. Spontaneous acute GVHD occurred in eight patients (72%). Five patients (45%) achieved complete remission, and the GVT effect was closely associated with GVHD. These results support the concept that GVT is effective against LM in patients who have been heavily pretreated. Further studies are needed to investigate strategies to generate more specific alloreactive effects providing optimal GVT and an acceptable risk of GVHD and infections.

摘要

非清髓性方案已被证明可在异基因干细胞移植(allo-SCT)后实现植入,且与操作相关的毒性最小。传统的allo-SCT可使复发难治性淋巴系统恶性肿瘤(LM)患者获得缓解,但这些良好结果可能是以高治疗相关发病率和死亡率为代价的。采用强度较低的方案进行allo-SCT可能会降低这些并发症的发生率,从而产生有效的移植物抗肿瘤效应(GVT)。我们展示了11例接受减强度方案allo-SCT的LM患者的数据。10例患者此前接受过高剂量治疗,存在高毒性风险,因此无法使用allo-SCT。氟达拉滨和低剂量白消安联合使用有助于植入并发挥GVT作用。血液学恢复迅速,急性移植物抗宿主病(GVHD)之前出现完全供体T细胞嵌合。GVHD和感染是主要问题。8例患者(72%)发生自发性急性GVHD。5例患者(45%)实现完全缓解,GVT效应与GVHD密切相关。这些结果支持了GVT对经过大量预处理的LM患者有效的概念。需要进一步研究来探索产生更具特异性的同种异体反应效应的策略,以提供最佳的GVT以及可接受的GVHD和感染风险。

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验